Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.

The level of minimal residual disease (MRD) in marrow predicts outcome and guides treatment in childhood acute lymphoblastic leukemia (ALL) but accurate prediction depends on accurate measurement.Forty-one children with ALL were studied at the end of induction. Two samples were obtained from each il...

Full description

Bibliographic Details
Main Authors: Sue Latham, Elizabeth Hughes, Bradley Budgen, Francoise Mechinaud, Catherine Crock, Henry Ekert, Peter Campbell, Alexander Morley
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5626434?pdf=render
id doaj-9c80a8251e89468ba768f2cd70d85421
record_format Article
spelling doaj-9c80a8251e89468ba768f2cd70d854212020-11-24T21:30:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011210e018555610.1371/journal.pone.0185556Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.Sue LathamElizabeth HughesBradley BudgenFrancoise MechinaudCatherine CrockHenry EkertPeter CampbellAlexander MorleyThe level of minimal residual disease (MRD) in marrow predicts outcome and guides treatment in childhood acute lymphoblastic leukemia (ALL) but accurate prediction depends on accurate measurement.Forty-one children with ALL were studied at the end of induction. Two samples were obtained from each iliac spine and each sample was assayed twice. Assay, sample and side-to-side variation were quantified by analysis of variance and presumptively incorrect decisions related to high-risk disease were determined using the result from each MRD assay, the mean MRD in the patient as the measure of the true value, and each of 3 different MRD cut-off levels which have been used for making decisions on treatment.Variation between assays, samples and sides each differed significantly from zero and the overall standard deviation for a single MRD estimation was 0.60 logs. Multifocal residual disease seemed to be at least partly responsible for the variation between samples. Decision errors occurred at a frequency of 13-14% when the mean patient MRD was between 10-2 and 10-5. Decision errors were observed only for an MRD result within 1 log of the cut-off value used for assessing high risk. Depending on the cut-off used, 31-40% of MRD results were within 1 log of the cut-off value and 21-16% of such results would have resulted in a decision error.When the result obtained for the level of MRD is within 1 log of the cut-off value used for making decisions, variation in the assay and/or sampling may result in a misleading assessment of the true level of marrow MRD. This may lead to an incorrect decision on treatment.http://europepmc.org/articles/PMC5626434?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sue Latham
Elizabeth Hughes
Bradley Budgen
Francoise Mechinaud
Catherine Crock
Henry Ekert
Peter Campbell
Alexander Morley
spellingShingle Sue Latham
Elizabeth Hughes
Bradley Budgen
Francoise Mechinaud
Catherine Crock
Henry Ekert
Peter Campbell
Alexander Morley
Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
PLoS ONE
author_facet Sue Latham
Elizabeth Hughes
Bradley Budgen
Francoise Mechinaud
Catherine Crock
Henry Ekert
Peter Campbell
Alexander Morley
author_sort Sue Latham
title Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
title_short Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
title_full Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
title_fullStr Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
title_full_unstemmed Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
title_sort sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description The level of minimal residual disease (MRD) in marrow predicts outcome and guides treatment in childhood acute lymphoblastic leukemia (ALL) but accurate prediction depends on accurate measurement.Forty-one children with ALL were studied at the end of induction. Two samples were obtained from each iliac spine and each sample was assayed twice. Assay, sample and side-to-side variation were quantified by analysis of variance and presumptively incorrect decisions related to high-risk disease were determined using the result from each MRD assay, the mean MRD in the patient as the measure of the true value, and each of 3 different MRD cut-off levels which have been used for making decisions on treatment.Variation between assays, samples and sides each differed significantly from zero and the overall standard deviation for a single MRD estimation was 0.60 logs. Multifocal residual disease seemed to be at least partly responsible for the variation between samples. Decision errors occurred at a frequency of 13-14% when the mean patient MRD was between 10-2 and 10-5. Decision errors were observed only for an MRD result within 1 log of the cut-off value used for assessing high risk. Depending on the cut-off used, 31-40% of MRD results were within 1 log of the cut-off value and 21-16% of such results would have resulted in a decision error.When the result obtained for the level of MRD is within 1 log of the cut-off value used for making decisions, variation in the assay and/or sampling may result in a misleading assessment of the true level of marrow MRD. This may lead to an incorrect decision on treatment.
url http://europepmc.org/articles/PMC5626434?pdf=render
work_keys_str_mv AT suelatham sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
AT elizabethhughes sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
AT bradleybudgen sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
AT francoisemechinaud sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
AT catherinecrock sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
AT henryekert sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
AT petercampbell sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
AT alexandermorley sourcesoferrorinmeasurementofminimalresidualdiseaseinchildhoodacutelymphoblasticleukemia
_version_ 1725964384887373824